Display options
Cite
Bradford A, Lees K. Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial. Curr Control Trials Cardiovasc Med. 2000;1(3):184-190doi: 10.1186/cvm-1-3-184.
Bradford, A., & Lees, K. (2000). Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial. Current controlled trials in cardiovascular medicine, 1(3), 184-190. https://doi.org/10.1186/cvm-1-3-184
Bradford, Andrew, and Lees, Kennedy. "Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial." Current controlled trials in cardiovascular medicine vol. 1,3 (2000): 184-190. doi: https://doi.org/10.1186/cvm-1-3-184
Bradford A, Lees K. Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial. Curr Control Trials Cardiovasc Med. 2000;1(3):184-190. doi: 10.1186/cvm-1-3-184. PMID: 11714436; PMCID: PMC56206.
Copy Download .nbib Format: NLM
Share it on

Curr Control Trials Cardiovasc Med. 2000;1(3):184-190. doi: 10.1186/cvm-1-3-184.

Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial.

Current controlled trials in cardiovascular medicine

Andrew Bradford, Kennedy Lees

Affiliations

  1. University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK. [email protected]

PMID: 11714436 PMCID: PMC56206 DOI: 10.1186/cvm-1-3-184

Abstract

The Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial is a multicentre,randomised, placebo-controlled trial of magnesium sulphate (MgSO4) funded by the UK Medical Research Council. When complete, it will be the largest single neuroprotective study undertaken to date. Conscious patients presenting within 12 h of acute stroke with limb weakness are eligible. The primary outcome measure is combined death and disability as measured using the Barthel Index at 90-day follow up. By randomizing 2700 patients, the study will have 84% power to detect a 5.5% absolute reduction in the primary end-point. By April 2000, 86 centres were participating, with representation in Canada, USA, Europe, South America, Singapore and Australia. So far, 1206 patients have been randomised, of whom 37% were treated within 6 h. Overall 3-month mortality was 20% and the primary outcome event rate was 43%. The study is ongoing and centres worldwide are encouraged to participate.

References

  1. Arch Phys Med Rehabil. 1979 Jan;60(1):14-7 - PubMed
  2. Am Heart J. 1984 Jul;108(1):188-93 - PubMed
  3. Lancet. 1994 Apr 2;343(8901):816-9 - PubMed
  4. Stroke. 1988 May;19(5):604-7 - PubMed
  5. Arch Int Pharmacodyn Ther. 1990 Mar-Apr;304:196-205 - PubMed
  6. Arch Phys Med Rehabil. 1994 Dec;75(12):1287-96 - PubMed
  7. Clin Sci (Lond). 1993 Aug;85(2):175-81 - PubMed
  8. J Neurosurg. 1996 Jul;85(1):117-24 - PubMed
  9. Br J Pharmacol. 1985 Feb;84(2):381-91 - PubMed
  10. Lancet. 1991 Jun 22;337(8756):1521-6 - PubMed
  11. Stroke. 1998 May;29(5):918-23 - PubMed
  12. Lancet. 1995 Jun 10;345(8963):1455-63 - PubMed
  13. Lancet. 1995 Mar 18;345(8951):669-85 - PubMed
  14. Am J Obstet Gynecol. 1987 Dec;157(6):1435-8 - PubMed
  15. Neurosci Lett. 1990 Feb 5;109(1-2):234-8 - PubMed
  16. Nature. 1984 Feb 2-8;307(5950):462-5 - PubMed
  17. Neuroscience. 1991;44(2):335-41 - PubMed
  18. N Engl J Med. 1995 Jul 27;333(4):201-5 - PubMed
  19. J Cereb Blood Flow Metab. 1991 Nov;11(6):1025-30 - PubMed
  20. Lancet. 2000 Jun 3;355(9219):1949-54 - PubMed
  21. Stroke. 1995 Jul;26(7):1183-8 - PubMed

Publication Types